Adverse Drug Reactions in Women's Health Care

Journal of Midwifery and Women's Health

Volumn 56, Issue 3, 2011, Pages 205-213

  Tharpe, Nell ^a  

^a NONE   (United States)

Author keywords

Adverse drug reaction reporting systems; Adverse drug reactions; Drug toxicity; Genetics; Polymorphism

Indexed keywords

ANTIBIOTIC AGENT; CITALOPRAM; CODEINE; CONTRAST MEDIUM; DIPHENHYDRAMINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMMUNOMODULATING AGENT; LORATADINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; TAMOXIFEN; VASOPRESSIN;

ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; BLISTER; BREAST CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TRANSFORMATION; EDEMA; FEMALE; FEVER; GENETIC VARIABILITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; HYPERSENSITIVITY REACTION; HYPONATREMIA; HYPOTENSION; IMMUNE RESPONSE; INCIDENCE; LIVER NECROSIS; LIVER TOXICITY; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SKIN EXFOLIATION; UNSPECIFIED SIDE EFFECT; URTICARIA; WHEEZING; WOMEN'S HEALTH;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG TOXICITY; FEMALE; HUMANS; MALE; RISK FACTORS; SEX FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 79955486439     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/j.1542-2011.2010.00050.x     Document Type: Review

References (30)

1. Psaty BM, Burke SP. Protecting the health of the public-Institute of Medicine recommendations on drug safety. N Engl J Med. 2006;355:1753-1755.
2. Moore TJ, Cohen MR. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167:1752-1759.
3. World Health Organization. International drug monitoring: the role of national centres. World Health Org Tech Rep Ser. 1972;498:1-25.
4. McLellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N Engl J Med. 2007;356:1700-1702.
5. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med. 2005;165:1363-1369.
6. Reidl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781-1790.
7. Whitley HP, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009;80:1254-1258.
8. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol. 2007;7:9.
9. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489-499.
10. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4:413-424.
11. Gandhi M, Aweeka F, Greenblat RM, Blachke TF. Sex differences in pharmacokinetics and pharmacodynamics. Ann Rev Pharmacol Toxicol. 2004;44:499-523.
12. Bernard S, Neville KA, Nuugyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the US populations and clinical implications. Oncologist. 2008;11:126-135.
13. Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000;28:1397-1400.
14. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827-2831.
15. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics. 2009;10:1467-1487.
16. Frank J. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72:1277-1282.
17. Manganelli G, Fico A, Martini G, Filosa S. Discussion on pharmacogenetic interaction in G6PD deficiency and methods to identify potential hemolytic drugs. Cardiovasc Hematol Disord Drug Targets. 2010;10:143-150.
18. Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res. 2008;14:5913-5918.
19. Wilkes JM, Clark LE Herrera JL. Acetaminophen overdose in pregnancy. South Med J. 2005;98:1118-1122.
20. Smith HS. Opioid Metabolism. Mayo Clin Proc. 2009;84:613-624.
21. Koren G, Cairsn J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.
22. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther. 2009;86:634-643.
23. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding. Can Fam Physician. 2007;53:33-35.
24. Demoly P. Drug allergies-unknown dangers to patients. Expert Opin Drug Saf. 2008;7:347-350.
25. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5:309-316.
26. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29:383-392.
27. Flores G, Perez-Patrigeon S, Cobos-Ayala C, Vergara Severe symptomatic hyponatremia during citalopram therapy-a case report. J BMC Nephrology. 2004, 5:2.
28. Agency for Healthcare Research and Quality. Reducing and Preventing Adverse Drug Events to Decrease Hospital Costs. Research in Action, 2001 Issue 1. AHRQ Publication Number 01-0020, March 2001. Rockville, MD Agency for Healthcare Research and Quality; Accessed May 29, 2010.
29. O'Connor N. FDA boxed warnings: how to prescribe drugs safely. Am Fam Physician 2010;81:298-303.
30. Food and Drug Administration. Adverse Event Reporting System. 2009. Accessed June 20, 2010.